Cerimon Pharmaceuticals develops and commercializes therapeutics for autoimmune diseases, inflammation, and pains.
Cerimon Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for autoimmune diseases, inflammation, and pains in the United States and Europe. It develops Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, including pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. Cerimon Pharmaceuticals, Inc. was founded in 2004 and is headquartered in South San Francisco, California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 26, 2005 | Series A | $70M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Phase4 Ventures | — | Series A |